Analyst Price Targets — SMMT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 11:57 am | — | H.C. Wainwright | $30.00 | $16.09 | TheFly | Summit Therapeutics price target lowered to $30 from $40 at H.C. Wainwright |
| January 14, 2026 11:54 am | — | Piper Sandler | $40.00 | $16.89 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT) |
| December 17, 2025 7:58 am | Etzer Darout | Summit Redstone Partners | $18.00 | $17.23 | StreetInsider | Barclays Upgrades Summit Therapeutics plc (SMMT) to Equalweight |
| October 21, 2025 10:42 am | — | H.C. Wainwright | $40.00 | $20.04 | StreetInsider | Summit Therapeutics plc (SMMT) PT Lowered to $40 at H.C. Wainwright |
| October 21, 2025 9:35 am | — | Barclays | $16.00 | $20.04 | TheFly | Summit Therapeutics price target raised to $16 from $13 at Barclays |
| September 16, 2025 9:04 pm | — | Summit Redstone Partners | $13.00 | $18.12 | TheFly | Summit Therapeutics initiated with an Underweight at Barclays |
| August 19, 2025 10:31 am | Kelsey Goodwin | Summit Redstone Partners | $21.00 | $25.71 | TheFly | Piper starts Summit Therapeutics with Neutral on high expectations |
| April 28, 2025 10:11 am | — | H.C. Wainwright | $44.00 | $24.11 | TheFly | Summit Therapeutics selloff Friday on data overdone, says H.C. Wainwright |
| April 25, 2025 5:55 pm | — | Wells Fargo | $30.00 | $23.47 | TheFly | Wells says Summit, Akeso data 'not the bull case,' but not 'bear case either' |
| April 25, 2025 1:56 pm | Kelly Shi | Jefferies | $44.00 | $25.61 | TheFly | Jefferies uncovers China approval for Summit Therapeutics, ups target |
Latest News for SMMT
Large-cap stocks surged last week as catalysts from short squeezes to innovation-driven momentum fueled broad gains.
Summit Therapeutics stock jumps as FDA accepts ivonescimab BLA. Strong trial data and partnerships boost confidence in its cancer therapy pipeline.
Ivonescimab is a PD-1xVEGF bispecific antibody under development for cancer, primarily for lung cancer.
Aberdeen Group plc lowered its stake in Summit Therapeutics PLC (NASDAQ: SMMT) by 18.6% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 927,171 shares of the company's stock after selling 212,359 shares during the period. Aberdeen
Summit Therapeutics (NASDAQ: SMMT - Get Free Report) and Cosmos Health (NASDAQ: COSM - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk. Analyst Ratings This is a summary of current
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SMMT.
U.S. House Trading
No House trades found for SMMT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.